Abstract
Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Current Vascular Pharmacology
Title:Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Volume: 13 Issue: 3
Author(s): Vasilios G. Athyros, Niki Katsiki and Asterios Karagiannis
Affiliation:
Keywords: microRNA, cardiovascular disease, obesity, metabolic syndrome, diabetes, antisense oligonucleotides, silencing, microRNA mimics.
Abstract: Several non-coding microRNAs (miRs) are implicated in the pathogenesis of obesity, metabolic syndrome, diabetes mellitus, atherosclerosis and cardiovascular disease. Some of these miRs are beneficial but others are hazardous. Silencing of the latter by antisense oligonucleotides has been attempted in animal models with promising results. However, the replacement of down-regulated beneficial miRs, by manufactured miR mimics, or increasing their expression is much more demanding and has several limitations. The treatment of cardiovascular diseases through miR manipulation shows potential, provided safety and cost effectiveness issues are considered carefully before implementation in humans.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Katsiki Niki and Karagiannis Asterios, Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/157016111303150707103801
DOI https://dx.doi.org/10.2174/157016111303150707103801 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Invasive Diagnostic Tools for Investigating Endothelial Dysfunction
Current Pharmaceutical Design Molecular Docking Studies and Pharmacophore Modeling of Some Insulin Mimetic Agents from Herbal Sources: A Rational Approach towards Designing of Orally Active Insulin Mimetic Agents
Current Traditional Medicine Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Prevention of Non-communicable Diseases by Balanced Nutrition: Population- specific Effective Public Health Approaches in Developing Countries
Current Diabetes Reviews Inflammasome Activation in Chronic Glomerular Diseases
Current Drug Targets Cerebral Microbleeds Do Not Predict Hemorrhagic Transformation in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Diuretics: From Classical Carbonic Anhydrase Inhibitors to Novel Applications of the Sulfonamides
Current Pharmaceutical Design Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications
Current Diabetes Reviews Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Current Diabetes Reviews Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Oxidative Stress in the ICU
Current Nutrition & Food Science Mapping of Type 1 Diabetes Mellitus
Current Diabetes Reviews Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research Editorial (Thematic Issue: Nanotechnology as a Strategy to Improve Treatment of Diabetes)
Current Pharmaceutical Biotechnology